Teicoplanin: an alternative drug for the treatment of COVID-19?


Journal

International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 04 03 2020
revised: 07 03 2020
accepted: 09 03 2020
pubmed: 18 3 2020
medline: 29 4 2020
entrez: 18 3 2020
Statut: ppublish

Résumé

In December 2019, a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged from China causing pneumonia outbreaks, first in the Wuhan region of China and then spread worldwide because of its probable high transmission efficiency. Owing to the lack of efficient and specific treatments and the need to contain the epidemic, drug repurposing appears to be the best tool to find a therapeutic solution. Chloroquine, remdesivir, lopinavir, ribavirin and ritonavir have shown efficacy to inhibit coronavirus in vitro. Teicoplanin, an antibiotic used to treat staphylococcal infections, previously showed efficacy to inhibit the first stage of the Middle East respiratory syndrome coronavirus (MERS-CoV) viral life cycle in human cells. This activity is conserved against SARS-Cov-2, thus placing teicoplanin as a potential treatment for patients with this virus.

Identifiants

pubmed: 32179150
pii: S0924-8579(20)30094-7
doi: 10.1016/j.ijantimicag.2020.105944
pmc: PMC7102624
pii:
doi:

Substances chimiques

Teicoplanin 61036-62-2

Types de publication

Editorial

Langues

eng

Sous-ensembles de citation

IM

Pagination

105944

Informations de copyright

Copyright © 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Références

N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Int J Antimicrob Agents. 2020 May;55(5):105938
pubmed: 32171740
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
J Biol Chem. 2016 Apr 22;291(17):9218-32
pubmed: 26953343
Int J Antimicrob Agents. 2020 Mar;55(3):105923
pubmed: 32070753
Int J Antimicrob Agents. 2016 Oct;48(4):349-52
pubmed: 27546219
Int J Antimicrob Agents. 2020 Apr;55(4):105933
pubmed: 32147516

Auteurs

Sophie Alexandra Baron (SA)

Aix-Marseille Université, IRD, APHM, MEPHI, Faculté de Médecine et de Pharmacie, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France.

Christian Devaux (C)

Aix-Marseille Université, IRD, APHM, VITROME, Faculté de Médecine et de Pharmacie, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France.

Philippe Colson (P)

Aix-Marseille Université, IRD, APHM, MEPHI, Faculté de Médecine et de Pharmacie, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France.

Didier Raoult (D)

Aix-Marseille Université, IRD, APHM, MEPHI, Faculté de Médecine et de Pharmacie, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France; IHU-Méditerranée Infection, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France.

Jean-Marc Rolain (JM)

Aix-Marseille Université, IRD, APHM, MEPHI, Faculté de Médecine et de Pharmacie, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France; IHU-Méditerranée Infection, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France. Electronic address: jean-marc.rolain@univ-amu.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH